Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study.

Related Articles

Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study.

Eur J Paediatr Neurol. 2015 Jan;19(1):37-40

Authors: Arkilo D, Hanna J, Dickens D, Justesen L, Brunn J, Garland S, Penovich P

Abstract
OBJECTIVE: To assess pregnancy outcomes on women exposed to monotherapy with antiepileptic agents.
METHODS: Questionnaires were sent to women with epilepsy in our practice who were pregnant between 2006 and 2011. 62/86 patients (72%) who responded were on monotherapy. 24 fetuses (63%) were exposed to lamotrigine, 11 (28%) to levetiracetam, 2 (5.2%) to topiramate, 1 (2.6%) to gabapentin, 17 (27%) to carbamazepine, 5 to phenytoin and 2 to valproate.
RESULTS: There were 55 (88%) live births and 7 unsuccessful pregnancies (miscarriages/stillbirths). Unsuccessful pregnancies were reported in 2/24 gestations exposed to lamotrigine, 2/11 to levetiracetam and 3/17 to carbamazepine. Delayed motor development or speech delay requiring therapy and special programming was noted in 2/24 children prenatally exposed to lamotrigine, 3/17 exposed to carbamazepine and 1/2 children exposed to valproate.
CONCLUSION: Our pilot study of children exposed to antiepileptic drug monotherapy in-utero demonstrated a favorable trend for successful pregnancy outcomes and developmental trajectory.

PMID: 25457510 [PubMed - indexed for MEDLINE]

from Speech via a.lsfakia on Inoreader http://ift.tt/1Y5L1AN
via IFTTT